Web Results

Law360 article - Shook, Hardy & Bacon


By Emily Field. Law360, New York (March 17, 2016, 11:30 PM ET) -- A Utah federal judge on Wednesday tossed claims, brought by a ... The case is Cerveny et al v. Sanofi et al., case number 2:14-cv-00545, in the U.S. District Court for the.

Amgen Inc. v. Sanofi et al - RPX Search


Amgen Inc. v. Sanofi et al. 1:14-cv-01393; Filed: 11/11/2014; Case Updated Daily ; Latest Docket Entry: 12/15/2014; PACER. Create Alert. ×.

Amgen Inc. v. Sanofi et al - Law360


Parties, docket activity and news coverage of federal case Amgen Inc. v. Sanofi et al, case number 1:14-cv-01414, from Delaware Court.

Antibody Conjugate Therapeutics: Challenges and Potential


Oct 15, 2011 ... Phase I. Sanofi/ImmunoGen. huB4-SPDB-DM4 .... Jeffrey SC, Torgov MY, Andreyka JB, Boddington L, Cerveny CG,. Denny WA, et al. ... V, et al. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer ...

Medical Countermeasures for Radiation Exposure and Related I ...


... dose rate, the quality of radiation, and the time and extent of bodily exposure (;; ). ... and either have been or are currently being developed for FDA approval (;;,). ..... 2 h after irradiation had lower efficacy than a pre-irradiation injection (i.e., 12 % vs. ..... (sargramostim) is 5–10 μg kg<sup>−1</sup> d<sup>−1</sup> sc or (200–400 μg m<sup>−2</sup> d<sup>−1</sup>) (;)...

New developments for antibody-drug conjugate-based therapeutic ...


Mar 7, 2016 ... SAR408701, Sanofi, 1, 2, Solid, CEACAM5, DM4, SPDB, Yes ..... 15; J.A. Francisco, C.G. Cerveny, D.L. Meyer, B.J. Mixan, K. Klussman, D.F. ..... D.S. Siegel, T.M. Zimmerman, S. Jagannath, N.C. Munshi, S. Lonial, V. Roy, et al.

Current methods for the synthesis of homogeneous antibody–drug ...


Behrens and Liu (2014) and Panowksi et al. ... Sanofi-Genzyme, Glycoengineering .... The importance of conjugation site was also described by Strop et al. ..... Barginear et al., 2012; M.F. Barginear, V. John, D.R. Budman ... B.A. Mendelsohn, C.G. Cerveny, D.F. Chace, R.L. DeBlanc, R.P. Gearing, T.D. Bovee, C.B. Siegall, et ...

Safety and activity of the anti-CD79B antibody–drug conjugate ...


Apr 26, 2015 ... Vss=volume of distribution at steady state. tmax=time to reach the maximum concentration. ..... CD19-targeted maytansinoid antibody–drug conjugate SAR3419 (Sanofi, Paris, .... 9Francisco, JA, Cerveny, CG, Meyer, DL et al.

Results of a Pivotal Phase II Study of Brentuximab Vedotin for ...


Jun 20, 2012 ... Abstract/FREE Full Text. ↵. Diehl V,; Franklin J,; Pfreundschuh M,; et al. ... Francisco JA,; Cerveny CG,; Meyer DL,; et al. (2003) cAC10-vcMMAE ...

Novel Agents for Follicular Lymphoma


Dec 4, 2010 ... The response rates and time to progression were similar (49% vs 43% and 7 months vs 10 months in arm A .... Calistoga, Johnson & Johnson, EMD Serono, sanofi-aventis, Millenium, Biotest, Cephalon, Pharmion, Eisai, ... Hagenbeek A,; Fayad L,; Delwail V,; et al. .... Baum PR,; Cerveny C,; Gordon B,; et al.

More Info

Aventis' Clomid Defeats Claims of Inadequate Warnings Based on ...


Mar 23, 2016 ... Plaintiff Victoria Cerveny allegedly took Clomid in September and October 1992. Shortly ... The case name is Cerveny et al v. Sanofi et al.

Biz Groups Back Aventis In 10th Circ. Label-Warning Fight - Law360


Sep 21, 2016 ... Cerveny, whose son was born missing two fingers, had claimed that Clomid labels didn't adequately warn of ... The case is Cerveny et al. v. Sanofi et al., case number 16-4050, in the U.S. Court of Appeals for the Tenth Circuit.

Current Status: Site-Specific Antibody Drug Conjugates - NCBI


Mar 22, 2016 ... Very recently, Zhang et al. introduced a different approach to reduce the ... In 2014, Sanofi-Genzyme published a combinatorial approach of beta-1 .... Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. ... Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al.